|1.||Interstitial Lung Diseases (Interstitial Lung Disease)
|5.||Myositis (Idiopathic Inflammatory Myopathies)
|1.||Lundberg, Ingrid E: 37 articles (12/2015 - 11/2002)|
|2.||Miller, Frederick W: 33 articles (09/2014 - 07/2002)|
|3.||Rider, Lisa G: 32 articles (09/2014 - 07/2002)|
|4.||Oddis, Chester V: 27 articles (11/2015 - 12/2003)|
|5.||Targoff, Ira N: 21 articles (11/2014 - 07/2002)|
|6.||Mimori, Tsuneyo: 17 articles (09/2015 - 09/2004)|
|7.||Reed, Ann M: 16 articles (09/2015 - 12/2003)|
|8.||Benveniste, Olivier: 16 articles (07/2015 - 03/2009)|
|9.||Selva-O'Callaghan, Albert: 15 articles (12/2015 - 10/2006)|
|10.||Dankó, Katalin: 15 articles (09/2015 - 02/2002)|
|1.||Intravenous Immunoglobulins (IVIG)FDA Link
06/01/1994 - "While IVIG may benefit some patients with refractory myositis, future studies must address the sustained efficacy of this agent."
12/01/2009 - "IVIg as add on treatment with MMF is effective in severe and refractory myositis, moreover as safe and steroid-sparing agent."
08/01/1996 - "The efficacy of polyvalent intravenous immunoglobulin therapy (IVIG) was evaluated in three patients with refractory myositis. "
10/01/2007 - "The clinical effects of high-dose IVIG on muscle function in patients with refractory inflammatory active myositis did not correspond to effects on any of the investigated molecules in our study. "
01/01/2016 - "IVIG is known to confer significant benefit in rheumatologic conditions, including inflammatory myopathy. "
|2.||rituximab (Mabthera)FDA Link
12/01/2011 - "CONCLUSION; Rituximab is an effective treatment in refractory inflammatory myopathies, showing a decrease in CPK and LDH, an increase in muscle strength and improvement in scores of disease activity, general health, functional ability and health related quality of life with sustained effect during a median of 27.1 months of follow-up."
03/01/2011 - "Rituximab is effective in the treatment of patients with idiopathic inflammatory myopathy."
02/01/2013 - "To assess the safety and efficacy of rituximab in a randomized, double-blind, placebo-phase trial in adult and pediatric myositis patients. "
01/01/2015 - "Biologic predictors of clinical improvement in rituximab-treated refractory myositis."
03/01/2014 - "To identify the clinical and laboratory predictors of clinical improvement in a cohort of myositis patients treated with rituximab. "
08/01/1996 - "Are intravenous immunoglobulin infusions beneficial in the treatment of inflammatory myopathies?"
10/01/2003 - "High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials."
07/01/1998 - "A prospective open label trial of add on therapy with intravenous immunoglobulin (i.v.Ig) was carried out in 16 patients with inflammatory myopathy who had continued to deteriorate or had relapsed on conventional therapy. "
05/12/2013 - "[Intravenous immunoglobulin treatment in idiopathic inflammatory myopathy]."
04/01/2012 - "Subcutaneous immunoglobulins in ocular myositis."
|4.||Cyclosporine (Ciclosporin)FDA LinkGeneric
07/01/1995 - "[The efficacy of cyclosporin in the treatment of myositis]."
04/01/2002 - "Three months later, a complete resolution of myositis had been obtained, and the cyclosporine was tapered off. "
07/01/1995 - "Cyclosporin A (CyA) was used in 15 patients with corticosteroid-resistant myositis (11) and as a first-line drug (4). "
04/15/1992 - "Generalized myositis in Behçet disease: treatment with cyclosporine."
01/01/1997 - "Cyclosporine was effective against both myositis and interstitial pneumonitis when used early in the course of the disease."
05/01/2013 - "The detection and characterization of a large array of autoantibodies, including at least 8 different antisynthetase, anti-SRP, -200/100 (HMGCR), -Mi-2, -CADM-140 (MDA5), -SAE, -p155, -MJ (NXP-2), and -PMS1, frequently associated with distinct and well-defined clinicopathological features, allowed for significant improvement in the definition and diagnosis of idiopathic inflammatory myopathies (IIM). "
12/01/2014 - "Children with anti-NXP2 autoantibodies had a greater degree of weakness (median lowest ever Childhood Myositis Assessment Score 29.6 vs 42) and were less likely to be in remission at 2 years post-diagnosis. "
03/01/2015 - "In addition, the combined determination of myositis-specific autoantibodies and SSA autoantibodies may help to accurately discriminate SCLE from CADM."
06/01/2009 - "Detection of myositis-specific autoantibodies is especially helpful in the diagnosis of early and atypical cases with features of overlapping disease."
09/30/2002 - "Recent developments in immunology have improved our knowledge and it is now possible to classify these disorders according to the presence of myositis specific autoantibodies. "
|6.||Prednisolone (Predate)FDA LinkGeneric
03/01/2003 - "Myositis with Sjögren's syndrome showed relatively moderate symptoms and responded well to prednisolone. "
05/01/2004 - "The present study was therefore undertaken to investigate how HMGB-1 is expressed in muscle tissue of patients with myositis and, if so, whether such expression is modulated by prednisolone therapy. "
12/01/2011 - "All these findings suggested a diagnosis of focal inflammatory myositis and the patient was put under oral prednisolone and physical therapy."
01/01/1999 - "We report two patients with biopsy-proven focal myositis, successfully treated with a peripheral arterial injection of low-dose prednisolone. "
01/01/1999 - "Focal myositis: magnetic resonance imaging findings and peripheral arterial administration of prednisolone."
12/01/2011 - "Myositis-specific antibodies have been helpful in defining subsets of patients with different responses to treatment and prognosis. "
06/01/2012 - "Our study suggests that inflammatory myopathies associated with anti-mitochondrial antibodies form a characteristic subgroup."
01/01/1994 - "To study the possible role of the virus dose, and of antiviral antibodies in the development of CB1 myositis, we infected groups of newborn mice with six CB1 doses, ranging from 30 to 10,000 plaque forming units (pfu); after 4 and 8 weeks we determined morbidity and antiviral antibody titer, and quantified histopathological changes. "
10/01/1992 - "A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies."
01/01/2016 - "Inflammatory myopathies: Anti-FHL1 antibodies linked to IIM."
|8.||Prednisone (Sone)FDA LinkGeneric
03/01/1998 - "Eighteen of 21 patients (85%) in the prednisone study group had resolution of myositis. "
04/15/2003 - "Eight patients received prednisone (60 mg/day) with 5 attaining complete resolution of myositis. "
08/01/2001 - "Thus, MRI and P-31 MRS are useful in assessing the status of patients with inflammatory myopathies during treatment with prednisone and immunosuppressive drugs."
11/01/2002 - "Most patients with a muscular dystrophy show improvement with prednisone treatment, although they will not be cured; many patients with idiopathic inflammatory myopathies are cured. "
10/01/1994 - "Each of five patients treated with oral prednisone for their cutaneous lesion or mild myositis after onset of their skin manifestations 3-12 years and had marked improvement. "
|9.||Adrenal Cortex Hormones (Corticosteroids)IBA
06/01/1991 - "Each of five patients treated with oral corticosteroids for their cutaneous disease had marked improvement and did not develop myositis. "
11/01/2000 - "Although corticosteroids remain the mainstay of treatment for the inflammatory myopathies, their use is complicated by many side effects. "
06/24/1989 - "This is an uncommon type of idiopathic myositis which involves males more often than females; it usually develops in elderly patients; its course is very slow; it is usually associated with distal weakness; neurophysiological studies show a mixed "myogenic" and "neurogenic" pattern; and it is usually unresponsive to corticosteroids. "
02/01/2016 - "Corticosteroids in Myositis and Scleroderma."
06/01/2015 - "It enrolled adults with myositis (by Bohan and Peter criteria) with active disease receiving corticosteroids. "
|10.||Tacrolimus (Prograf)FDA LinkGeneric
09/01/2011 - "We performed an observational clinical study, the effects of tacrolimus (FK506) on the thymic output in patients with refractory inflammatory myopathies. "
09/01/2011 - "The effects of FK506 on refractory inflammatory myopathies."
08/01/2005 - "Tacrolimus is a well-tolerated and effective therapy for managing refractory ILD and myositis in anti-aaRS-positive patients."
04/01/2004 - "This case represents a tacrolimus-associated myositis."
04/01/2004 - "Tacrolimus-associated myositis: a case report in a renal transplant patient."
04/01/2003 - "Improved understanding of the molecular mechanisms of muscle injury in the inflammatory myopathies should lead to the development of more specific forms of immunotherapy for these conditions."
02/01/2013 - "Targeted immunotherapy trials for idiopathic inflammatory myopathies."
11/01/2011 - "[Immunotherapy of myositis: future prospects]."
06/01/2011 - "Immunotherapy of inflammatory myopathies: practical approach and future prospects."
03/01/2010 - "Immunotherapy of myositis: issues, concerns and future prospects."
01/01/2012 - "Immunomodulatory therapy was required in all patients and was effective for both MG and inflammatory myopathies, except for one autopsy case. "
11/01/2009 - "Immunomodulatory therapy was required for all patients and was effective for both MG and inflammatory myopathies, although 1 patient died. "
01/01/2014 - "Inflammatory myopathies, sporadic IBM excluded, are amenable to immunosuppressive and immunomodulation therapies. "
09/01/2009 - "Idiopathic inflammatory myopathies (IIM) are diseases that are potentially amenable to immunomodulatory therapy. "
11/01/1993 - "Although there have been considerable advances in our understanding of the immunopathogenesis of the different forms of autoimmune inflammatory myopathy, the treatment of these conditions remains largely empirical, being based upon the use of immunosuppressive and immunomodulatory therapies which, for the most part, are non-selective in their actions. "
|3.||Drug Therapy (Chemotherapy)
09/01/2003 - "In the two cases, myositis appeared 3 and 5.5 months after the completion of radiation therapy and 2 and 2.5 months after the beginning of chemotherapy, respectively. "
09/01/2003 - "Chemotherapy-induced radiation recall myositis."
06/01/2001 - "The myositis progressed despite chemotherapy directed at the underlying malignant disorder and immunosuppressive treatment. "
02/01/1992 - "Although the mechanism involved in occurrence of inflammatory myositis associated with pregnancy or delivery are not clarified, these patient indicated a presence of subset of PM/DM which do not require intensive drug therapy."
04/01/2015 - "Most clinicians believe that treatment of the primary tumor may contribute to an improvement of myositis, and in our case, tumor resection and chemotherapy were effective. "
08/01/2015 - "Myositis is a category IV indication for plasmapheresis."
11/01/1988 - "This experience with plasmapheresis in myositis supplements a substantial reported experience of benefit from this therapy."
09/01/1981 - "Idiopathic inflammatory myopathy and plasmapheresis."
09/01/1981 - "Thirty-five patients with idiopathic inflammatory myopathy (IM) were treated with plasmapheresis. "
09/01/1981 - "Plasmapheresis in idiopathic inflammatory myopathy. "
04/01/2011 - "The mainstay of treatment for the idiopathic inflammatory myopathies currently and traditionally has been therapeutics aimed at suppressing or modifying the immune system. "
03/01/2012 - "In this review, we discuss molecular effects of currently prescribed GCs on skeletal muscle and also discuss the current state of development of GC analogues as alternative therapeutics for inflammatory muscle diseases."